Subtopic Deep Dive

Adenosine A2A Receptor Signaling
Research Guide

What is Adenosine A2A Receptor Signaling?

Adenosine A2A receptor signaling refers to the G protein-coupled receptor pathways activated by adenosine binding to A2A receptors, primarily coupling to Gs proteins to elevate cAMP levels and modulate immune and neuronal functions.

A2A receptors are expressed on immune cells, neurons, and other tissues, mediating anti-inflammatory effects through cAMP-dependent protein kinase A activation (Fredholm et al., 2011, 1264 citations). Key studies highlight A2A involvement in regulatory T cell suppression via CD39/CD73-generated adenosine (Deaglio et al., 2007, 2333 citations). Over 10 papers from the provided list detail pharmacology, neuroprotection, and classification (Borea et al., 2018, 714 citations).

Curated Papers

Key Challenges

Why It Matters

A2A receptor signaling suppresses inflammation in regulatory T cells, offering targets for autoimmune disease therapies (Deaglio et al., 2007). In neuroprotection, A2A blockade prevents excitotoxicity, relevant for Parkinson's and stroke treatments (Cunha, 2005; Fredholm et al., 2005). Antagonists like caffeine modulate brain function via A2A, impacting Alzheimer's pathology (Ribeiro and Sebastião, 2010). Tumor microenvironments exploit A2A for immune evasion, guiding cancer immunotherapies (Di Virgilio and Adinolfi, 2016).

Key Research Challenges

Receptor Subtype Selectivity

Developing selective A2A agonists/antagonists remains difficult due to structural similarities with A2B and A3 receptors (Fredholm et al., 2011). Off-target effects complicate therapeutic applications in inflammation and neuroprotection (Borea et al., 2018).

Tissue-Specific Signaling

A2A signaling varies by cell type, with Gs-cAMP dominance in immune cells but heterodimerization effects in neurons (Fredholm et al., 2005). Quantifying context-dependent pathways challenges modeling (Cunha, 2005).

Pathological Dysregulation

Upregulation in tumors promotes immune suppression, requiring strategies to block without systemic immunosuppression (Di Virgilio and Adinolfi, 2016). Balancing repair signals in distress hinders repair therapies (Fredholm, 2007).

Essential Papers

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

Silvia Deaglio, Karen M. Dwyer, Wenda Gao et al. · 2007 · The Journal of Experimental Medicine · 2.3K citations

The study of T regulatory cells (T reg cells) has been limited by the lack of specific surface markers and an inability to define mechanisms of suppression. We show that the expression of CD39/ENTP...

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update

Bertil B. Fredholm, Adriaan P. IJzerman, Kenneth A. Jacobson et al. · 2011 · Pharmacological Reviews · 1.3K citations

In the 10 years since our previous International Union of Basic and Clinical Pharmacology report on the nomenclature and classification of adenosine receptors, no developments have led to major cha...

Foxp3-dependent programme of regulatory T-cell differentiation

Marc A. Gavin, Jeffrey P. Rasmussen, Jason D. Fontenot et al. · 2007 · Nature · 1.1K citations

Pharmacology of Adenosine Receptors: The State of the Art

Pier Andrea Borea, Stefania Gessi, Stefania Merighi et al. · 2018 · Physiological Reviews · 714 citations

Adenosine is a ubiquitous endogenous autacoid whose effects are triggered through the enrollment of four G protein-coupled receptors: A 1 , A 2A , A 2B , and A 3 . Due to the rapid generation of ad...

Adenosine and Brain Function

Bertil B. Fredholm, Jiang‐Fan Chen, Rodrigo A. Cunha et al. · 2005 · International review of neurobiology · 681 citations

Adenosine, an endogenous distress signal, modulates tissue damage and repair

Bertil B. Fredholm · 2007 · Cell Death and Differentiation · 681 citations

Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase

Patrizia Pellegatti, Lizzia Raffaghello, Giovanna Bianchi et al. · 2008 · PLoS ONE · 653 citations

Our results show that ATP in the tumour interstitium is in the hundreds micromolar range, while it is basically undetectable in healthy tissues. Here we show that a chimeric plasma membrane-targete...

Reading Guide

Foundational Papers

Start with Fredholm et al. (2011, 1264 citations) for A2A classification and nomenclature; Deaglio et al. (2007, 2333 citations) for immune suppression mechanisms; Fredholm et al. (2005) for brain function context.

Recent Advances

Borea et al. (2018, 714 citations) reviews pharmacology state-of-the-art; Di Virgilio and Adinolfi (2016, 542 citations) covers tumor roles; Ribeiro and Sebastião (2010) on caffeine antagonism.

Core Methods

Gs-coupling via cAMP assays (Borea et al., 2018); CD39/CD73 ectoenzyme activity for adenosine generation (Deaglio et al., 2007); heterodimerization with dopamine receptors (Fredholm et al., 2005).

How PapersFlow Helps You Research Adenosine A2A Receptor Signaling

Discover & Search

Research Agent uses citationGraph on Deaglio et al. (2007) to map 2333-citing papers linking A2A to Tregs, then exaSearch for 'A2A receptor cAMP immune suppression' to uncover 50+ related works. findSimilarPapers expands from Fredholm et al. (2011) for pharmacological updates.

Analyze & Verify

Analysis Agent applies readPaperContent to extract cAMP pathway details from Borea et al. (2018), verifies claims with CoVe against Fredholm et al. (2011), and runs PythonAnalysis for dose-response curve fitting from Cunha (2005) data using SciPy, graded by GRADE for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in A2A neuroprotection via contradiction flagging between Fredholm et al. (2005) and Cunha (2005), while Writing Agent uses latexEditText for pathway diagrams, latexSyncCitations for 10-paper bibliography, and latexCompile for review manuscripts. exportMermaid visualizes G-protein coupling cascades.

Use Cases

"Analyze cAMP elevation kinetics in A2A signaling from regulatory T cell papers"

Research Agent → searchPapers('A2A cAMP Tregs') → Analysis Agent → runPythonAnalysis (pandas curve fitting on Deaglio 2007 data) → matplotlib plot of dose-response.

"Draft LaTeX review on A2A receptor pharmacology with citations"

Synthesis Agent → gap detection (Borea 2018 + Fredholm 2011) → Writing Agent → latexEditText (intro section) → latexSyncCitations → latexCompile → PDF with figures.

"Find code for A2A signaling simulations from recent papers"

Research Agent → searchPapers('A2A signaling model code') → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Jupyter notebook.

Automated Workflows

Deep Research workflow scans 50+ papers via searchPapers on 'A2A receptor signaling', structures report with citationGraph from Deaglio et al. (2007), and GRADE-scores therapeutic claims. DeepScan applies 7-step CoVe to verify A2A-cAMP links in Fredholm et al. (2005). Theorizer generates hypotheses on A2A-tumor interactions from Di Virgilio and Adinolfi (2016).

Try Doxa for Adenosine A2A Receptor Signaling Research

Frequently Asked Questions

What defines A2A receptor signaling?

A2A receptors couple to Gs proteins, increasing adenylyl cyclase activity and cAMP to activate PKA, modulating inflammation and neurotransmission (Fredholm et al., 2011).

What are key methods in A2A studies?

Radioligand binding assays measure affinity; FRET imaging tracks cAMP dynamics; knockout mice reveal physiological roles (Borea et al., 2018).

What are landmark papers?

Deaglio et al. (2007, 2333 citations) links A2A to Treg suppression; Fredholm et al. (2011, 1264 citations) standardizes nomenclature (Borea et al., 2018).

What open problems exist?

Selective A2A modulators without off-targets; tissue-specific signaling quantification; combining A2A blockade with immunotherapy in tumors (Di Virgilio and Adinolfi, 2016).